TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06444048

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EV68-228-N
Description: EV68-228-N is a recombinant human monoclonal IgG1 antibody which is produced by genetically engineered plasmids in Nicotiana benthamiana. This intervention is directed against enterovirus EV-D68 capsid protein potentially providing treatments for EV-D68 infection and AMF.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EV68-228-N
Description: EV68-228-N is a recombinant human monoclonal IgG1 antibody which is produced by genetically engineered plasmids in Nicotiana benthamiana. This intervention is directed against enterovirus EV-D68 capsid protein potentially providing treatments for EV-D68 infection and AMF.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EV68-228-N
Description: EV68-228-N is a recombinant human monoclonal IgG1 antibody which is produced by genetically engineered plasmids in Nicotiana benthamiana. This intervention is directed against enterovirus EV-D68 capsid protein potentially providing treatments for EV-D68 infection and AMF.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for EV68-228-N
Description: The placebo is a sterile buffer solution formulated to match the EV68-228-N Drug Product. The formulation is 20mM Citrate + 10 mM Glycine, 8% Sucrose, and 0.01% Polysorbate 80, with a target pH of 5.5. The placebo will be filled into glass vials at 10 mL per vial. The formulation buffer is a clear colorless liquid.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for EV68-228-N
Description: The placebo is a sterile buffer solution formulated to match the EV68-228-N Drug Product. The formulation is 20mM Citrate + 10 mM Glycine, 8% Sucrose, and 0.01% Polysorbate 80, with a target pH of 5.5. The placebo will be filled into glass vials at 10 mL per vial. The formulation buffer is a clear colorless liquid.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for EV68-228-N
Description: The placebo is a sterile buffer solution formulated to match the EV68-228-N Drug Product. The formulation is 20mM Citrate + 10 mM Glycine, 8% Sucrose, and 0.01% Polysorbate 80, with a target pH of 5.5. The placebo will be filled into glass vials at 10 mL per vial. The formulation buffer is a clear colorless liquid.
Study: NCT06244615

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Verum (WO 6607)
Description: Mouth and throat rinse and gargle solution

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (WO 6608)
Description: Mouth and throat rinse and gargle solution
Study: NCT06506279

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CorTec Brain Interchange (BIC) System
Description: Surgical implantation of the BIC System. This study's main objective is to implement and evaluate neuroplasticity-inducing stimulation. The stimulation methods for inducing neuroplasticity have been selected based on prior preclinical and intraoperative work that has shown promise in providing rehabilitative benefits for stroke patients.
Study: NCT05156398

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rimegepant
Description: Rimegepant 75mg or 50mg (2 X 25mg) ODT

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo 75mg or 50mg (2 X 25mg) ODT
Study: NCT04743141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimegepant (PF-07899801)
Description: Rimegepant 75 mg, 50 mg or 35 mg ODT
Study: NCT05910476

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: a high dose of statin/ezetimib
Description: In randomization, 100 patients will proceed with Rosuvastatin/Ezetimib 20/10 mg and 100 patients will proceed with Atovastatin/Ezetimib 40/10 mg.~A new generation of drug elution stents can be inserted and later registered, and if the patient agrees to participate in the study, they are randomly assigned after stent implantation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: a high dose of statin/ezetimib
Description: In randomization, 100 patients will proceed with Rosuvastatin/Ezetimib 20/10 mg and 100 patients will proceed with Atovastatin/Ezetimib 40/10 mg.~A new generation of drug elution stents can be inserted and later registered, and if the patient agrees to participate in the study, they are randomly assigned after stent implantation.
Study: NCT06391255

Intervention type: OTHER
Intervention: scintigraphy
Description: oesophageal and gastric emptying
Study: NCT05367713

Intervention type: OTHER
Intervention: patients having had an osteitis of the cranial flap after craniectomy
Description: description of management and failure of cranial flap after craniectomy
Study: NCT05152368

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloRx
Description: cultured allogeneic adult umbilical cord derived mesenchymal stem cells
Study: NCT05392166

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: blood glucose, blood gases, serum electrolytes, HbA1c, complete blood count and serum creatinine. Serum calcium, serum amylase, serum lipase and serum triglycerides , abdominal ultrasound
Description: blood samples will be collected at admission for assessment of blood glucose, blood gases, serum electrolytes, HbA1c, complete blood count and serum creatinine. Serum calcium, serum amylase, serum lipase and serum triglycerides will be assessed within the first 24 hours after hospital admission. For the control group, the blood samples will be collected during the pediatric diabetes clinic follow-up visits. Abdominal ultrasound will be done to all the study participants.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: blood glucose, blood gases, serum electrolytes, HbA1c, complete blood count and serum creatinine. Serum calcium, serum amylase, serum lipase and serum triglycerides , abdominal ultrasound
Description: blood samples will be collected at admission for assessment of blood glucose, blood gases, serum electrolytes, HbA1c, complete blood count and serum creatinine. Serum calcium, serum amylase, serum lipase and serum triglycerides will be assessed within the first 24 hours after hospital admission. For the control group, the blood samples will be collected during the pediatric diabetes clinic follow-up visits. Abdominal ultrasound will be done to all the study participants.
Study: NCT05702970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sucrosomial iron
Description: Sucrosomial iron group: administration of sucrosomial iron (SiderAl Forte®) at a dose of 60 mg (2 tablets) once a day for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sucrosomial iron
Description: Sucrosomial iron group: administration of sucrosomial iron (SiderAl Forte®) at a dose of 60 mg (2 tablets) once a day for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: administration Vitamin D3 (100,000 IU load at time 0, then 2,000 IU daily) for 24 weeks in combination with of sucrosomial iron (SiderAl Forte®) at a dose of 60 mg (2 tablets) once daily in Sucrosomial iron and vitamin D group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric Carboxymaltose 50 MG/ML
Description: Control group \[standard of care\]: administration of FCM (Ferinject®) with a dose between 500 and 2000 mg (depending on body weight and Hb values), to be administered in 1 or 2 doses (time 0 ± 6 weeks) with possible additional administration of 500 mg at week 12 in case of persistent ID.
Study: NCT04717895

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Rocking environment forward (B) followed by a translation environment
Description: Start by the virtual reality session by viewing a rocking environment followed by a translation environment

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Translation environment followed by a rocking environment
Description: Start by the virtual reality session by viewing a translation environment followed by a rocking environment
Study: NCT05894772

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Power over Pain Portal
Description: Youth from different ages, sexes, gender, sexual orientations, races, dwelling and school/employment status will receive access to the Power over Pain Portal for 4 months. The portal consists of self-assessment tools (bi-weekly check-ins to provide users with feedback on their mood, anxiety, pain, and sleep and guide decision making on choice of interventions), evidence-based virtual educational (pain neuroscience) and cognitive behavioural therapy (CBT) pain interventions that are delivered in a stepped care manner based on participant needs/preference. The overall objective is to determine the implementation (guided by Proctor's implementation conceptual framework) and clinical effectiveness of the PoP Portal in a sample of youth (12-18 years of age) who are on the waitlist for tertiary care consultation at any pediatric CP clinic in Canada.
Study: NCT04157075

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivicaine injection into uterosacral ligaments prior to colpotomy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Description: Bupivicaine injection into uterosacral ligaments prior to colpotomy

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Bupivacaine
Description: Bupivicaine injection into uterosacral ligaments prior to colpotomy
Study: NCT06278740

Intervention type: DIAGNOSTIC_TEST
Intervention: Musculoskeletal Ultrasound
Description: Upper extremity pathologies of participants with ultrasound

Intervention type: DIAGNOSTIC_TEST
Intervention: Musculoskeletal Ultrasound
Description: Upper extremity pathologies of participants with ultrasound
Study: NCT05778487

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gatorade Thirst Quencher
Description: Gatorade Thirst Quencher, 710ml (45g of carbohydrates, 6.3% carbohydrates, 25.4kcal/100ml)
Study: NCT05200897

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transdermal trigeminal electrical neuromodulation(Cefaly)
Description: The Cefaly device delivers electrical micro-impulses through a self-adhesive electrode which is placed over the participant's forehead, where the supratrochlear and supraorbital branches of the ophthalmic division of the trigeminal nerve are located. Rectangular, biphasic impulses with an electrical mean equal to zero are transmitted. The impulse width is 250μs, frequency is 60Hz, and the maximum intensity of 16mA is over 14 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transdermal trigeminal electrical neuromodulation(Cefaly)
Description: The Cefaly device delivers electrical micro-impulses through a self-adhesive electrode which is placed over the participant's forehead, where the supratrochlear and supraorbital branches of the ophthalmic division of the trigeminal nerve are located. Rectangular, biphasic impulses with an electrical mean equal to zero are transmitted. The impulse width is 250μs, frequency is 60Hz, and the maximum intensity of 16mA is over 14 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transdermal trigeminal electrical neuromodulation(Cefaly)
Description: The Cefaly device delivers electrical micro-impulses through a self-adhesive electrode which is placed over the participant's forehead, where the supratrochlear and supraorbital branches of the ophthalmic division of the trigeminal nerve are located. Rectangular, biphasic impulses with an electrical mean equal to zero are transmitted. The impulse width is 250μs, frequency is 60Hz, and the maximum intensity of 16mA is over 14 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transdermal trigeminal electrical neuromodulation(Cefaly)
Description: The Cefaly device delivers electrical micro-impulses through a self-adhesive electrode which is placed over the participant's forehead, where the supratrochlear and supraorbital branches of the ophthalmic division of the trigeminal nerve are located. Rectangular, biphasic impulses with an electrical mean equal to zero are transmitted. The impulse width is 250μs, frequency is 60Hz, and the maximum intensity of 16mA is over 14 minutes
Study: NCT05379231

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BiCROS fitting
Description: Each participant will be fitted with the experimental CROS device on the unaidable ear and with a compatible hearing aid on the other ear.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monaural hearing aid fitting
Description: Each participant will be fitted with a hearing aid on the better hearing ear and no device on the unaidable ear.~Monaural hearing aid fitting acts as control intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unaided condition
Description: No treatment, i.e. the participants are not fitted with a CROS device and/ or hearing aid.~Unaided condition acts as control intervention.
Study: NCT05888194

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mucogyne® gel
Description: In Mucogyne group, each eligible patient will receive a box of Mucogyne® gel. The patient will apply Mucogyne® gel, 48-hours after delivery, everyday, twice a day, massaging it into the intimate area, for a 10-day period.
Study: NCT06242093

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: whole body vibrator
Description: • WBVT and Conservative treatment Group A will receive WBVT with conservative treatment. The treatment will be given with the frequency of 34 times/week for 25-30 minutes with the help of Galileo vibration platform

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GROUP B Pelvic floor muscle training (PFMT) and conservative treatment.
Description: Pelvic floor muscle training (PFMT) and conservative treatment.~Group B will receive (PFMT) with conservative treatment. The PMFT group will be educated to do each exercise in 3-4 set with 15-20 repetitions and a 60-second relax between each set.~Time: 3-4 Times/WEEK for 8 weeks
Study: NCT05883839

Intervention type: OTHER
Intervention: Student Group
Description: Sexual Healthcare Questionnaire will be applied to nursing students to adapt it to Turkish.
Study: NCT05589740

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally tailored healthy eating advice
Description: Culturally-tailored education includes strategies for healthy eating, preferences for traditional healthy foods, recommendations for limiting unhealthy traditional foods, portion sizes, etc.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard healthy eating advice
Description: Standard healthy eating education includes strategies, foods, portions, and cooking and eating tips for general dietary recommendations from USDA My Plate
Study: NCT06022172

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MOTIVATIONAL INTERVIEW BASED ON THE CALGARY FAMILY INTERVENTION MODEL IN PARENTS WITH A CHILD WITH CEREBRAL PALS.
Description: Motivational interview based on Calgary family intervention model in parents of children with cerebral palsy.~Introductory information form, caregiving burden, parent self-efficacy and stress coping styles scale will be used.
Study: NCT05616845

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Picterus Jaundice Pro
Description: Use Picterus Jaundice Pro, a smartphone app that is used to take photo of the newborns skin, where the Picterus calibration card is place.
Study: NCT05264636

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sucrose
Description: Sucrose Beverage

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Steviol Glycosides
Description: Steviol Glycoside Beverage
Study: NCT06148350

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stroke Rehabilitation
Description: Both the groups received interventions three days/week for 30-60 minutes for four weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stroke Rehabilitation
Description: Both the groups received interventions three days/week for 30-60 minutes for four weeks
Study: NCT06119555

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cinnamon Capsules
Description: The intervention consists of four cinnamon capsules (each 1.5 grams, totaling 3 grams) a day, with two with breakfast and two with dinner for 60 days
Study: NCT05587608

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: combined thoracic segmental spinal epidural anesthesia
Description: ultrasound guided thoracic segmental spinal anesthesia at the level of T10 interlaminar space , patients will be in sitting position, spinal needle is then introduced through the epidural needle not more than 0.5 cm beyond the Dura matter. 2cc of heavy Marcaine plus 25 ug fentanyl are injected through the spinal needle.
Study: NCT04544124

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency management
Description: Incentives will be provided for treatment attendance over a 12-week period.
Study: NCT05481970

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine,ketamine,lidocaine,propofol
Description: Group (A): Induction of general anesthesia will be done using lidocaine (1.5 mg/kg), propofol (2-3 mg/kg), and atracurium (0.5 mg/kg). Dexmedetomidine 0.5 µg/kg over 10 min, started 10 min before induction. Following tracheal intubation, dexmedetomidine infusion generally will be initiated at 0.6 μg/kg/h and titrated between 0.2 and 1.0 μg/kg/h according to the heart rate maintaining bispectral index (BIS) between 40-60, lidocaine (1.5 mg/kg/h). ketamine will be given as a bolus dose of 0.3 mg/kg after induction and prior to skin incision then 0.2 mg/kg/h as an infusion. Patients will receive dexamethasone (8 mg i.v.) after induction.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: fentanyl,propofol
Description: In group (B) for induction of anesthesia, patients will receive propofol 2-3mg/kg, fentanyl 1-2mcg/kg and atracurium 0.5 mg/kg as a muscle relaxant to facilitate intubation. Fentanyl bolus doses of 0.5-1 mcg/kg will be given to keep BIS score 40-60 during surgery.
Study: NCT06293950

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WJMSC
Description: - Patients receive three intravenous doses of MSCs (1 million/kg) every two weeks as treatment.
Study: NCT05254652

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine 30mg
Description: Case management consists confirmation of hospital visit date, checking the adverse effect and treatment compliance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine 30mg
Description: Case management consists confirmation of hospital visit date, checking the adverse effect and treatment compliance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 150mg
Description: Case management consists confirmation of hospital visit date, checking the adverse effect and treatment compliance.
Study: NCT04961476

Intervention type: DIETARY_SUPPLEMENT
Intervention: 1-MNA
Description: 1-MNA supplementation
Study: NCT04846972

Intervention type: BEHAVIORAL
Intervention: FASTRACS intervention
Description: Intervention (4 steps) :~* Penultimate to last chemotherapy : patient will receive tools of the intervention~* 1 month after the end of oncological treatment (OT): patient will attend a general medicine consultation with the GP RTW checklist~* 2 months after OT: patient will attend a pre RTW visit with the OP RTW checklist~* 5 months after the end of OT: if the patient has not returned to work 10 months after inclusion, they will have a visit with an OP-RTW to work coordinator~Self-questionnaires will evaluate quality of life (EORTC QLQC30, BR23, Euroqol (EQ-5D-5L)), anxiety and depression (HAD), employment status, self-efficacy to return to work (RTW-SE11), pre-RTW and RTW visit with the OP, social support, care consumption, physical activity (short IPAQ), perceived performance (WRF), work conditions. The implementation and use of the intervention tools will also be assessed: the patient guide, the employer guide, RTW checklists for the GP and the OP.
Study: NCT04716010

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Participants will complete a shopping task in the online grocery store, and the products that contain red meat will not have warning labels or a 30% increase in price.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warning Labels
Description: While completing the shopping task in the online grocery store, the health and environmental warning labels will appear next to the image of every product that contains red meat.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tax
Description: While completing the shopping task in the online grocery store, all products containing red meat will have a 30% increase in price.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined Warning Labels and Tax
Description: While completing the shopping task in the online grocery store, all products containing red meat will have the health and environmental warning labels appear next to the product image and a 30% increase in price.
Study: NCT04624672

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide (1 Mg Dose)
Description: Weekly injection of study drug for 4-6 months prior to Roux-en-Y gastric bypass surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Weekly injection of placebo for 4-6 months prior to Roux-en-Y gastric bypass surgery
Study: NCT05980676

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Two-Week Email-Based Program
Description: Both intervention groups will complete an activity that will guide the creation of a habitual instigation implementation intention (e.g., When I finish eating lunch at work, then I will put on my walking shoes and go outside) and receive a 2-week long personalized email campaign. The Coached group will be able to reply to the emails to give feedback, ask questions, and receive additional support.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Two-Week Email-Based Program
Description: Both intervention groups will complete an activity that will guide the creation of a habitual instigation implementation intention (e.g., When I finish eating lunch at work, then I will put on my walking shoes and go outside) and receive a 2-week long personalized email campaign. The Coached group will be able to reply to the emails to give feedback, ask questions, and receive additional support.
Study: NCT05480501

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IM19 CAR-T cells
Description: IM19 CAR-T cells administrated in a dosage to be selected by physician from a specific range.
Study: NCT06092086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratinib
Description: Continuous daily PO dosing of lorlatinib 100mg QD.
Study: NCT05478538

Intervention type: PROCEDURE
Intervention: Core Needle or Forceps Biopsy
Description: Subjects must be clinically able, at investigator discretion, to undergo additional core needle or forceps biopsy passes during their biopsy. These additional biopsies may either be collected from the primary tumor or a metastatic site amenable to additional passes (e.g., liver or lymph nodes) per the clinician.
Study: NCT05418725

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PVI and Linear lesion using PEF
Description: PVI and Linear lesion using PEF

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PVI and Linear lesion using CFRF
Description: PVI and Linear lesion using CFRF